Researchers from Janssen Pharmaceutica NV reported the discovery of novel potent fluoroallylamide induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors for the treatment of hematologic malignancies.

Researchers from Welab Barcelona presented the discovery and preclinical evaluation of novel analgesic candidates with a dual mode of action.

Researchers from CNRS and the Université d'Orléans presented the discovery of novel inhibitors of LIM kinases (LIMKs) as potential therapeutic candidates for the treatment of osteosarcoma (OS).

Researchers from Centre National de la Recherche Scientifique and affiliated organizations presented the discovery and preclinical identification of novel inhibitors of metallo-beta-lactamases (MBLs). Synthesis and optimization of novel broad-spectrum inhibitors against most relevant MBLs, such as VIM-type enzymes and NDM-1, led to the identification of JMV-7061 as the lead from the series.

Mas-related G-protein coupled receptor X2 (MRGPRX2) is expressed particularly on mast cells and its activation leads to the mast cell degranulation with release of inflammatory mediators.

Genentech Inc. presented data on structure-based lead optimization of orally bioavailable hematopoietic progenitor kinase 1 (HPK1) inhibitors. HPK1 is a negative regulator of T-cell receptor signaling in human T cells and target inhibition significantly increases cytokine production, such as IFN-gamma, TNF-alpha and IL-2, and T-cell proliferation, suggesting HPK1 inhibition as an intracellular T-cell target for cancer immunotherapy.